It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the future developments expected in the treatment paradigm of multiple sclerosis.
The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Question:
- What developments do you expect to see in the future treatment paradigm of MS?
Disclosures:
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
